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Abstract
Preeclampsia is a complication of pregnancy primarily characterized by hypertension and proteinuria and affects other organs as
well. The underlying causes are not yet fully understood. However, it is suggested that angiogenic factors of the placenta, genetic
factors, a malfunctioning immune system, and oxidative stress all play a role in causing preeclampsia. Currently, the only definitive
cure known for preeclampsia is delivery of the baby. Management of the condition includes taking preventative measures as well
as drugs such as labetalol and MgSO4. This paper analyzes mechanisms of preeclampsia and determines the possible causes
and most effective ways to manage the condition.
Introduction
Preeclampsia (PE) is a multisystem complication that
occurs during pregnancy and is primarily characterized
by elevated blood pressure and abnormally high levels of
protein in the urine. The disorder manifests itself after the
20th week of gestation and can lead to serious complications, possibly even fatality of the mother and the baby. It
can also cause long-term health conditions. The disease
has a worldwide prevalence of 5-8% of pregnancies and
currently ranks as one of the leading causes of maternal
and perinatal morbidity (Pennington et al., 2012). In addition to hypertension and proteinuria, afflicted patients
may undergo other symptoms including edema of the face
and hands, headaches, dizziness, decreased urination, nausea, and vision changes. Furthermore, 10-20% of women
with severe cases of PE can develop a potentially lethal
condition known as the HELLP syndrome, characterized
by the fundamental features of “hemolysis, elevated liver
enzyme levels, and low platelets.” If PE progressively
worsens, it can turn into eclampsia, where the elevated
blood pressure causes the mother to experience seizures
and may result in a coma (Preeclampsia. 2016).
The exact etiology of PE remains unknown. The purpose of this review is to determine the possible causes of
PE and the most effective therapeutic approaches available to manage the condition.
Methods
This comprehensive review was conducted based on critical
analyses of data collected from various databases accessed
through Touro College’s online library, such as ProQuest
and PubMed. The National Center for Biotechnology
(NCBI) website was also a useful tool in providing additional sources. Key words and phrases used to retrieve
data include “mechanisms of preeclampsia,” “causes of preeclampsia,” and “management of preeclampsia.”
Discussion
PE can be classified into an early onset and late onset
form. Women suffering from early-onset PE are diagnosed
before their 34th week of pregnancy and symptoms of
low birth weight and intrauterine growth restriction will
manifest. Conversely, the late onset form expresses itself
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after the 34th week and its cause is generally associated
with various maternal conditions including obesity, diabetes, and chronic kidney diseases. Regardless of the subtype, it is evident in all cases of PE that the placenta plays a
central role in its pathophysiology (Lisowska et al., 2018).
In normal pregnancies, an increase in blood flow to the
uterus will occur to ensure sufficient supply for the intervillous spaces and overall proper fetal development.
Cytotrophoblasts invade deep inside the maternal spiral
arteries to establish a vascular network and remodeling
subsequently takes place to form high-capacity blood vessels. This mechanism is defective in the placentas of individuals destined to develop PE. In such cases, the cytotrophoblasts fail to entirely convert from their proliferative
epithelial form into their invasive endothelial form. As a
result, remodeling of the spiral arteries is greatly hindered
and the restricting maternal vessels will lead to placental
ischemia (Rana et al., 2019).
Another identifying feature found to be associated with
the pathogenesis of this disorder is elevated levels of an antiangiogenic protein called soluble fms-like tyrosine kinase
(sFLT1) in the placenta (Roberts & Bell, 2013). This was
furthered studied on non-human primates. A group of animals was induced with uteroplacental ischemia (UPI) while
a Sham group of animals was not. The concentration of
plasma sFLT1 of both animal groups was measured over a
two-week period and the results were compared. As seen
in Figure 1, the UPI animals showed a significant increase
in sFLT-1 over time, whereas the Sham group’s sFLT1 levels
remained roughly unchanged (Makris et al., 2007). This experiment shows how reduced blood flow directly increases the amount of circulating sFLT1 in the plasma.
SFLT-1 is a soluble receptor that binds to the angiogenic factors, vascular endothelial growth factor (VEGF) and
placental growth factor (PlGF), and inhibits them from interacting with their receptors, Flt1 and Flk1. When they
cannot bind to their receptors, the angiogenic factors are
incapable of carrying out their function of promoting the
growth of new blood vessels. Therefore, the presence of
sFLT1 inhibits the growth of blood vessels. In PE, the excessive amount of sFLT1 abnormally constricts the mother’s
blood vessels, leading to hypertension, in addition to affecting the function of various other organs. The constricted
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with hypertension, there must be a “systolic
blood pressure greater than or equal to 140
mmHg and/or diastolic blood pressure greater than or equal to 90 mmHg” (Hinkosa et al.,
2020). A retrospective study of the databases
from two hospitals identified 362 women
who had chronic hypertension that required
treatment prior to their pregnancies were
analyzed. The data revealed that the percentage of superimposed PE in these women was
23.2%, a percentage notably higher than that
of the general population. (Lecarpentier et al.,
2013).
Autoimmune diseases like systemic lupus
erythematosus and antiphospholipid antibody syndrome, diabetes type 1 or 2, and
chronic arterial hypertension are other conditions classified as high-risk factors for PE
Figure 1:The concentration of plasma sFLT1 levels are significantly elevated in the UPI (Mayrink et al., 2018).
group in comparison to the sFLT1 of the Sham group (Makris et al., 2007).
Other risk factors known to be linked
blood vessels are also responsible for causing the kidneys
with PE include nulliparity, maternal age over 35, multito release proteins into the urine (Roberts & Bell, 2013).
fetal pregnancy, prior case of PE, chronic kidney disease,
prior stillbirth, and a pre-pregnancy BMI over 25. Data
Etiology of PE
was extracted and pooled from 92 studies regarding the
The causes of placental malformation are still being rerelative risk of developing PE for women with each risk
searched and currently remain unclear. It is understood,
factor. Pooling of the data is helpful in bringing about rehowever, that anything causing oxidative stress to the
sults that are as reliable as possible.
placenta is likely to cause PE. Oxidative stress is when
there is an imbalance between reactive oxygen species
Genetic Factors
(ROS) and antioxidants which disrupts metabolism and
Currently, there are no identified genes that are directcell signaling in aerobic organisms. Several cell compartly responsible to cause the disorder. However, because
ments can produce ROS, such as the mitochondria, endoclustering of PE among families is common, it is suggestplasmic reticulum, and nuclear membrane. They produce
ed that there must be a genetic etiological component
O2•− anions as a byproduct of auto-oxidation during the
involved. Women with a first relative that developed PE
electron transport chain. ROS can also be produced as a
have a three to five-fold increased risk of getting it as
result of arachidonic acid metabolism. Oxidative stress
well (Hansen et al., 2018). There is also research suggestregulates the transcription factors NRF2 and FoxO which
ing that paternal genes may be a contributing risk factor
control the expression of genes that detoxify oxidizing
for the development of PE as well. Women who became
molecules. Thus, the imbalance causes an interruption in
pregnant from a man that has had a previous partner with
the detoxification process and can lead to structural and
preeclampsia were seen to be at a slightly higher risk for
physiological damage to DNA, RNA, proteins, and lipids.
PE (Galaviz-Hernandez et al., 2018).
(Auoache et al., 2018). Oxidative stress is known to cause
endothelial cell dysfunction which can contribute to PE
Mother’s Immune Responses
(Duhig et al., 2016).
PE is thought to be a disorder that may be due to malfunctioning of the mother’s immune system. The syncytial
Risk Factors for PE
surface of the placenta sheds particles, ranging from large
Several principle risk factors were found to be associated
deported multinuclear fragments to sub-cellular comwith the onset of PE.The presence of certain medical conponents, and it is suggested that these particles contain
ditions can make a woman more prone to developing PE.
proteins that trigger an inflammatory response. In PE, the
Hypertension has strongly proven to be correlated with
number of circulating particles present increases, indicating
an increase in one’s risk of developing PE. To be diagnosed
a relationship between excess particles and the pathology
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of the disease. Thus, preeclampsia is characterized by an
exaggerated inflammatory response (Palei et al., 2013).
Furthermore, complications of the maternal immunity
mechanisms can be a causing factor of PE. During pregnancy, it is essential for the mother’s regulatory CD4 + T cells
to interact with the uterine natural killer cells in order to
recognize and accept the fetal antigens and enable placental growth. Failure of this process leads to a spontaneous
miscarriage, while a partial failure leads to poor placentation and dysfunction of the placental perfusion and chronic
immune activation that stems from the placenta. Women
with PE were found to have decreased levels of circulating
regulatory CD4 + T cells. Additionally, they have increased
levels of T helper 17 cells, cells that are also upregulated in
various autoimmune disorders (Palei et al., 2013).
Possible Complications of PE During Pregnancy
When symptoms of PE become severe, it can lead to
dangerous complications for both the mother and the
fetus, including fatality. Severe PE is when one or more of
the following conditions is present: blood pressure of 160
mmHg or higher for systolic and 110 mmHg diastolic on
at least two occasions that are at least 6 hours apart, at
least 2 g of proteinuria in a 24 urine specimen or on two
urine samples collected at least 4 hours apart, oliguria of
less than 500 mL in 24 hours, cerebral or visual issues,
pulmonary edema, pain in the epigastric or right upper
quadrant, fetal growth restriction, a persistent and severe
headache, or medical issues involving acute renal insufficiency, hepatic hematoma, and HELLP syndrome (Nankali
et al., 2013). It is said that 25% of PE cases are classified as
severe (Minire et al., 2013).
The mother may develop HELLP syndrome, which
causes mortality in 25% of affected women.This can bring
about a variety of complications that can affect many different organ systems such as the central nervous system,
renal system, respiratory system, and liver. Complications
include stroke, cerebral edema, retinal blindness, pulmonary edema, laryngeal edema, jaundice, renal failure, liver
failure, HELLP syndrome, and eclampsia. Globally, preeclampsia and eclampsia are responsible for 10-15% of all
maternal deaths (Nankali et al., 2013)
As for the fetus, the baby is often deprived of receiving
a sufficient amount of blood and does not get the oxygen
and nutrients it needs. Development under such conditions will be hindered, and the baby will have fetal growth
restriction, causing it to be very small at birth. Often, these
babies will need to be hospitalized for a period following
their birth. A stillbirth can happen if the placenta separates from the uterine wall, causing the mother to heavily
bleed. This is more likely to happen if the mother has a
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more severe case of PE, including the HELLP syndrome
(Preeclampsia research at the NICHD.2012). Infants
whose mothers had PE during their pregnancy also have
an increased risk of developing some long-term health
conditions due to the lack of proper development, such
as “learning disorders, cerebral palsy, epilepsy, deafness,
and blindness. Later on, they may be at risk for diabetes,
congestive heart failure, and hypertension. Infant death is
also a possible occurrence (Preeclampsia research at the
NICHD.2012).
Management Options for PE
Because of the severity of the complications that preeclampsia may cause, women should take several precautions to help lower their risk of developing the disorder.
Antiplatelet drugs, primarily low dose aspirin, are useful
preventative agents as they reduce the risk of PE by 19%
as well as decreasing the risk of stillbirth or neonatal death
by 16% (Duley et al., 2006). Aspirin is effective because it
reduces platelet aggregation, but it is also a risk of in utero
cerebral hemorrhage (Atallah et al., 2017). It is advised
that women at high risk should begin taking this before
12 weeks until 36 weeks of gestation (English et al., 2015).
Calcium supplementation during pregnancy also appears to reduce the risk of hypertensive disorders in
pregnancy, including PE. A group of 579 women were
assigned as a placebo group and a group of 588 women
were given calcium supplementation. When comparing
the percentage of hypertensive disorders of pregnancy
in the placebo and calcium groups of women, the calcium group had a significantly lower risk of hypertensive
disorders, particularly after the 28th week of gestation.
There seem to be no side effects associated with calcium
supplementation (Belizan et al., 1991).
There is also some research suggesting that antioxidant
supplementation of vitamins C and E may be useful in
lowering one’s risk of PE. These agents are thought to
prevent ROS from inflicting oxidative damage and overall
restoring the redox equilibrium. This therapy aims to ultimately prevent endothelial cell dysfunction, which is an
important pathological feature of PE (Aouache R. et al.,
2018). However, there are studies that show contradictory results about the effectiveness of these supplements
on reducing risks of PE. To test their outcomes related
to PE, women who were 9 weeks to 16 weeks pregnant
were examined until delivery. 5,088 women were given
daily antioxidant supplementation of vitamins C and E,
whereas 5,066 women served as a placebo group. The
vitamins did not have much of an effect on the risk of developing PE. Based on such findings, they do not seem to
serve any significant preventative purpose (Preeclampsia
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Research at the NICHD 2012).
Early and accurate detection of the disorder is important in order to provide immediate optimal management. Therefore, closely monitoring changes in pregnancy, especially for women who classify as high-risk, is
recommended. Regularly assessing blood pressure can
catch any hypertension which is a good indicator of
PE (Mayrink et al., 2018). Consistent urinary analyses
should be performed in order to check for proteinuria,
another big marker of PE. Monitoring growth often is
useful in identifying signs of fetal growth restriction as
well (English et al., 2015).
It is certain that the only definitive cure for PE is
delivery. The decision to deliver the fetus prematurely
is often based on two factors, estimated fetal weight
and the severity of the disorder. If the mother is experiencing “uncontrolled severe hypertension that is
not responding to therapy, eclampsia, acute pulmonary
edema, abruptio placentae, subcapsular hepatic hematoma, or thrombocytopenia <50,000/mm3 ”, then that indicates a need for immediate delivery (Uzan et al., 2011).
Nevertheless, there are various ways to help control the
condition during the pregnancy. Premature birth of the
fetus is almost always inevitable, since the mother will
most likely be unable to survive the full pregnancy period due to her destructive conditions. However, it is ideal
to allow the baby to develop for as long as possible to
improve neonatal outcomes. Mainly, it is important to
allow the fetal lungs to mature. Prolonging treatment
for as much as possible will result in the most beneficial
outcome for the fetus (Le et al., 2019).
If blood pressure reaches the level of 160/110 mmHg
or higher, antihypertensive treatment is a necessity as this
is considered a medical emergency. Oral antihypertensive
medications such as labetalol, methyldopa, and nifedipine
should be administered. If the oral therapy fails to elicit
a response, intravenous medication such as a labetalol
infusion or hydralazine should be given. However, the
commencement of treatment may result in a drop in
blood pressure that can affect uteroplacental circulation
and cause fetal distress; hence, the dosage of these drugs
should be titrated gradually (English et al., 2015).
Magnesium sulfate (MgSO4) is a drug that aids in preventing eclampsia. The drug should be administered to
women at high risk for eclamptic seizures. It has also been
shown to lower the risk of cerebral palsy in the offspring.
MgSO4 does have some adverse effects and can lead to
paralysis, an absence of reflexes, a lower respiratory rate,
and arrhythmias. Therefore, patients will need to have
their pulse, respiratory rate, and reflexes continuously
monitored in the time following. In the case that toxicity

does occur, it can be corrected by giving the patient calcium gluconate (English et al., 2015).
Conclusion
PE is a disorder that is not fully understood yet. Due to
the limited knowledge of its precise mechanisms, it remains
difficult to determine the exact etiology of the disorder.
However, the reviewed research articles were all consistently in agreement that women with the disease have
a common pathophysiological finding. Elevated levels of
sFLT1 are present in the placenta, which suggests the disease is largely due to dysfunctional angiogenic factors. The
inability of the mother’s angiogenic factors to bind to their
correct receptors causes her blood vessels to constrict
and leads to manifestations of PE (Roberts & Bell, 2013).
This seems to be the major factor behind the disorder.
PE does not have any known cures; the only way to
successfully stop the disease would be to terminate the
gestation period and deliver the baby. The goal would
be to manage and prolong the pregnancy for as long as
possible in a way that takes both the mother’s and fetus’
safety into account (Uzan et al., 2011). After reviewing
the various treatment options available, it seems that a
combination of therapeutic agents would be the most
viable approach for PE. Taking low-dose aspirin is a useful
protecting drug as it reduces platelet aggregation (Atallah
et al., 2017). Anti-hypertensive medication is essential
to control the mother’s blood pressure in cases when
it reaches 160/110 mmHg or higher. The use of anti-hypertensives can lead to a sudden drop in blood pressure
that can cause fetal distress, so it is important to responsibly monitor women’s blood pressure when they are on
these medications. Additionally, MgSO4 is important for
preventing or treating seizures in eclampsia (English et al.,
2015). Side effects that may present include paralysis, an
absence of reflexes, a lower respiratory rate, and arrhythmias. However, the drug is vastly advantageous, and monitoring the patient and regulating drug administrations will
eliminate most of the harm it can cause (English et al.,
2015). Knowledge of the various factors that put women
at high risk for PE is also useful for preventative care.
Women should have their blood pressure monitored to
check for hypertension, and urinalyses monitored to look
for proteinuria, two major symptoms of PE. (Mayrink et
al., 2018). Taking these steps can help in early detection
and management of PE.
References
Aouache, R., Biquard, L., Vaiman, D., & Miralles, F. (2018).
Oxidative stress in preeclampsia and placental diseases.
International Journal of Molecular Sciences, 19(5), 1496.
55

Adina Hadi

doi:10.3390/ijms19051496
Atallah, A., Lecarpentier, E., Goffinet, F., Doret-Dion, M.,
Gaucherand, P., & Tsatsaris, V. (2017). Aspirin for prevention of preeclampsia. Drugs (New York, N.Y.), 77(17),
1819-1831. doi:10.1007/s40265-017-0823-0
Bartsch, E., Medcalf, K. E., Park, A. L., & Ray, J. G. (2016).
Clinical risk factors for pre-eclampsia determined in early
pregnancy: Systematic review and meta-analysis of large
cohort studies. Bmj, 353, i1753. doi:10.1136/bmj.i1753
Belizan, J. M., Villar, J., Gonzalez, L., Campodonico, L., &
Bergel, E. (1991). Calcium supplementation to prevent
hypertensive disorders of pregnancy. The New England
Journal of Medicine, 325(20), 1399-1405. doi:10.1056/
NEJM199111143252002
Duhig, K., Chappell, L. C., & Shennan, A. H. (2016).
Oxidative stress in pregnancy and reproduction. London,
England: SAGE Publications.
Duley, L., Meher, S., & Abalos, E. (2006). Management of
pre-eclampsia. Bmj, 332(7539), 463-468. doi:10.1136/
bmj.332.7539.463
English, F. A., Kenny, L. C., & McCarthy, F. P. (2015). Risk
factors and effective management of preeclampsia.
Integrated Blood Pressure Control, 8(default), 7-12.
doi:10.2147/IBPC.S50641
Galaviz-Hernandez, C., Sosa-Macias, M., Teran, E., GarciaOrtiz, J. E., & Lazalde-Ramos, B. P. (2018). Paternal determinants in preeclampsia. Frontiers in Physiology, 9, 1870.
doi:10.3389/fphys.2018.01870
Hansen, A. T., Bernth Jensen, J. M., Hvas, A., & Christiansen,
M. (2018). The genetic component of preeclampsia:
A whole-exome sequencing study. PloS One, 13(5),
e0197217. doi:10.1371/journal.pone.0197217
Hinkosa, L., Tamene, A., & Gebeyehu, N. (2020). Risk factors associated with hypertensive disorders in pregnancy in nekemte referral hospital, from july 2015 to june
2017, ethiopia: Case-control study. BMC Pregnancy and
Childbirth, 20(1), 16. doi:10.1186/s12884-019-2693-9
Le, Y., Ye, J., & Lin, J. (2019). Expectant management of
early-onset severe preeclampsia: A principal component
analysis. Annals of Translational Medicine, 7(20), 519.
doi:10.21037/atm.2019.10.11
Lecarpentier, E., Tsatsaris, V., Goffinet, F., Cabrol, D., Sibai,
B., & Haddad, B. (2013). Risk factors of superimposed
preeclampsia in women with essential chronic hypertension treated before pregnancy. PloS One, 8(5), e62140.
doi:10.1371/journal.pone.0062140
Lisowska, M., Pietrucha, T., & Sakowicz, A. (2018).

56

Preeclampsia and related cardiovascular risk: Common
genetic background. Current Hypertension Reports,
20(8), 1-8. doi:10.1007/s11906-018-0869-8
Makris,A.,Thornton, C.,Thompson, J.,Thomson, S., Martin,
R., Ogle, R., et al. (2007). Uteroplacental ischemia results
in proteinuric hypertension and elevated sFLT-1. Kidney
International, 71(10), 977-984. doi:10.1038/sj.ki.5002175
Mayrink, J., Costa, M. L., & Cecatti, J. G. (2018).
Preeclampsia in 2018: Revisiting concepts, physiopathology, and prediction. TheScientificWorld, 2018, 6268276-9.
doi:10.1155/2018/6268276
Minire, A., Mirton, M., Imri, V., Lauren, M., & Aferdita,
M. (2013). Maternal complications of preeclampsia. Medicinski Arhiv, 67(5), 339-341. doi:10.5455/
medarh.2013.67.339-341
Nankali, A., Nankali, A., Malek-khosravi, S., Malek-khosravi,
S., Zangeneh, M., Zangeneh, M., et al. (2013). Maternal
complications associated with severe preeclampsia. The
Journal of Obstetrics and Gynecology of India, 63(2), 112115. doi:10.1007/s13224-012-0283-0
Palei, A. C., Spradley, F. T., Warrington, J. P., George, E. M.,
& Granger, J. P. (2013). Pathophysiology of hypertension
in pre-eclampsia: A lesson in integrative physiology. Acta
Physiologica, 208(3), 224-233. doi:10.1111/apha.12106
Preeclampsia (2016). https://medlineplus.gov/genetics/
condition/preeclampsia/#inheritance
Preeclampsia research at the NICHD. (2012).
https://www.nichd.nih.gov/newsroom/resources/
spotlight/101812-preeclampsia
Rana, S., Lemoine, E., Granger, J., & Karumanchi, S.
(2019). Preeclampsia: Pathophysiology, challenges, and
perspectives. Circulation Research, 124(7), 1094-1112.
doi:10.1161/CIRCRESAHA.118.313276
Roberts, J. M., & Bell, M. J. (2013). If we know so much about
preeclampsia, why haven’t we cured the disease? Journal
of Reproductive Immunology, 99(1), 1-9. doi:10.1016/j.
jri.2013.05.003
Uzan, J., Carbonnel, M., Piconne, O., Asmar, R., & Ayoubi,
J. (2011). Pre-eclampsia: Pathophysiology, diagnosis, and
management. Vascular Health and Risk Management, 7,
467-474. doi:10.2147/VHRM.S20181

